Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference
Altimmune (Nasdaq: ALT), a clinical-stage biopharmaceutical company, has announced its upcoming participation in the Guggenheim SMID Cap Biotech Conference. The company's management team will engage in a fireside chat scheduled for Wednesday, February 5, 2025, at 9:30 a.m. EST.
Interested parties can access the session through a webcast available in the Events section of the Altimmune website. This participation represents an opportunity for investors and stakeholders to gain insights into the company's developments and strategic direction.
Altimmune (Nasdaq: ALT), un'azienda biomedica in fase clinica, ha annunciato la sua partecipazione imminente alla Guggenheim SMID Cap Biotech Conference. Il team di gestione dell'azienda parteciperà a una conversazione informale programmata per mercoledì 5 febbraio 2025, alle 9:30 EST.
Le parti interessate possono accedere alla sessione tramite un webcast disponibile nella sezione Eventi del sito web di Altimmune. Questa partecipazione rappresenta un'opportunità per investitori e stakeholder di ottenere informazioni sui progressi e la direzione strategica dell'azienda.
Altimmune (Nasdaq: ALT), una empresa biofarmacéutica en etapa clínica, ha anunciado su próxima participación en la Conferencia Guggenheim SMID Cap Biotech. El equipo directivo de la empresa participará en una charla informal programada para miércoles, 5 de febrero de 2025, a las 9:30 a.m. EST.
Las partes interesadas pueden acceder a la sesión a través de una transmisión web disponible en la sección de Eventos del sitio web de Altimmune. Esta participación representa una oportunidad para que inversores y partes interesadas obtengan información sobre los desarrollos y la dirección estratégica de la empresa.
Altimmune (Nasdaq: ALT), 임상 단계의 생명공학 회사가 구겐하임 SMID 캡 생명공학 콘퍼런스에 곧 참여할 것이라고 발표했습니다. 회사의 경영 팀은 2025년 2월 5일 수요일 오전 9시 30분 EST에 예정된 파이어사이드 채팅에 참여할 예정입니다.
관심 있는 당사자들은 Altimmune 웹사이트의 이벤트 섹션에서 제공되는 웹캐스트를 통해 이 세션에 접근할 수 있습니다. 이번 참여는 투자자와 이해관계자에게 회사의 개발 및 전략적 방향에 대한 통찰력을 얻을 수 있는 기회를 제공합니다.
Altimmune (Nasdaq: ALT), une entreprise biopharmaceutique en phase clinique, a annoncé sa prochaine participation à la Conférence Guggenheim SMID Cap Biotech. L'équipe de direction de l'entreprise participera à une discussion informelle prévue pour mercredi 5 février 2025, à 9h30 EST.
Les parties intéressées peuvent accéder à la session via un webdiffusion disponible dans la section Événements du site web d'Altimmune. Cette participation constitue une opportunité pour les investisseurs et les parties prenantes d'obtenir des informations sur les développements et l'orientation stratégique de l'entreprise.
Altimmune (Nasdaq: ALT), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, hat seine bevorstehende Teilnahme an der Guggenheim SMID Cap Biotech Conference bekannt gegeben. Das Management-Team des Unternehmens wird an einem geplanten Kamin-Gespräch am Mittwoch, den 5. Februar 2025, um 9:30 Uhr EST teilnehmen.
Interessierte Parteien können über einen Webcast auf die Sitzung zugreifen, der im Bereich Veranstaltungen der Altimmune-Website verfügbar ist. Diese Teilnahme bietet Investoren und Interessengruppen die Möglichkeit, Einblicke in die Entwicklungen und strategische Ausrichtung des Unternehmens zu erhalten.
- None.
- None.
GAITHERSBURG, Md., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference. Details are as follows:
| Conference: | Guggenheim SMID Cap Biotech Conference | |
| Date/Time: | Wednesday, February 5, 2025, at 9:30 a.m. EST | |
The session will be webcast and can be accessed by visiting the Events section of the Altimmune website.
About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Company Contact:
Greg Weaver
Chief Financial Officer
Phone: 240-654-1450
ir@altimmune.com
Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com
Media Contact:
Danielle Cantey
Inizio Evoke, Biotech
Phone: 619-826-4657
Danielle.cantey@inizioevoke.com
FAQ
When is Altimmune (ALT) presenting at the Guggenheim SMID Cap Biotech Conference 2025?
How can investors watch Altimmune's (ALT) presentation at the Guggenheim Conference?
What type of presentation will Altimmune (ALT) give at the Guggenheim SMID Cap Conference?
Where is the Altimmune (ALT) Guggenheim Conference presentation taking place?
